{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:02:32Z","timestamp":1790596952294,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,19]],"date-time":"2027-05-19T00:00:00Z","timestamp":1810684800000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.joca.2026.03.116","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:37:41Z","timestamp":1773765461000},"page":"806-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening of an FDA-approved drug library reveals MEK1\/2 inhibitors block production of osteoarthritis mediators in activated human chondrocytes and synovial fibroblasts"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-1987","authenticated-orcid":false,"given":"Philip R.","family":"Coryell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-893X","authenticated-orcid":false,"given":"Jorge G.","family":"Fernandez Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Yanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-5421","authenticated-orcid":false,"given":"Kenneth H.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Loeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.joca.2026.03.116_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jama.2020.22171","article-title":"Diagnosis and treatment of hip and knee osteoarthritis: A review","volume":"325","author":"Katz","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.joca.2026.03.116_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41572-025-00594-6","article-title":"Osteoarthritis","volume":"11","author":"Tang","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.joca.2026.03.116_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12272-025-01551-3","article-title":"Emerging concepts and challenges in the development of disease-modifying osteoarthritis drugs - a more refined perspective","volume":"48","author":"Jenei-Lanzl","year":"2025","journal-title":"Arch. Pharm. Res"},{"issue":"2","key":"10.1016\/j.joca.2026.03.116_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41584-025-01332-8","article-title":"Osteoarthritis as a systemic disease","volume":"22","author":"Collins","year":"2026","journal-title":"Nat. Rev. Rheuma"},{"issue":"2","key":"10.1016\/j.joca.2026.03.116_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.joca.2020.09.006","article-title":"Transcriptional response of human articular chondrocytes treated with fibronectin fragments: an in vitro model of the osteoarthritis phenotype","volume":"29","author":"Reed","year":"2021","journal-title":"Osteoarthr. Cartil."},{"issue":"11","key":"10.1016\/j.joca.2026.03.116_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308647","article-title":"A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery","volume":"19","author":"Coryell","year":"2024","journal-title":"PLoS ONE"},{"issue":"809","key":"10.1016\/j.joca.2026.03.116_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adf8299","article-title":"Redox-active endosomes mediate alpha5beta1 integrin signaling and promote chondrocyte matrix metalloproteinase production in osteoarthritis","volume":"16","author":"Miao","year":"2023","journal-title":"Sci. Signal"},{"key":"10.1016\/j.joca.2026.03.116_bib8","article-title":"Response eQTLs, chromatin accessibility, and 3D chromatin structure in chondrocytes provide mechanistic insight into osteoarthritis risk","volume":"5","author":"Kramer","year":"2025","journal-title":"Cell Genom."},{"issue":"1","key":"10.1016\/j.joca.2026.03.116_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1063-4584(97)80029-5","article-title":"Prevalence of degenerative morphological changes in the joints of the lower extremity","volume":"5","author":"Muehleman","year":"1997","journal-title":"Osteoarthr. Cartil."},{"issue":"8","key":"10.1016\/j.joca.2026.03.116_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/art.11209","article-title":"The combination of insulin-like growth factor 1 and osteogenic protein 1 promotes increased survival of and matrix synthesis by normal and osteoarthritic human articular chondrocytes","volume":"48","author":"Loeser","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.joca.2026.03.116_bib11","series-title":"Assay Guidance Manual","year":"2004"},{"issue":"5","key":"10.1016\/j.joca.2026.03.116_bib12","first-page":"847","article-title":"A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients","volume":"43","author":"Yazici","year":"2025","journal-title":"Clin. Exp. Rheuma"},{"issue":"24","key":"10.1016\/j.joca.2026.03.116_bib13","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1128\/MCB.24.24.10954-10964.2004","article-title":"Ras\/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP\/p300 recruitment","volume":"24","author":"Foulds","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"42","key":"10.1016\/j.joca.2026.03.116_bib14","doi-asserted-by":"crossref","first-page":"35081","DOI":"10.1074\/jbc.C500353200","article-title":"Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1","volume":"280","author":"Monje","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.joca.2026.03.116_bib15","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1021\/acs.jmedchem.0c01609","article-title":"Potent and selective mitogen-activated protein kinase kinase 1\/2 (MEK1\/2) heterobifunctional small-molecule degraders","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.joca.2026.03.116_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/2229-5178.115538","article-title":"Ingenol mebutate: a novel topical drug for actinic keratosis","volume":"4","author":"Aditya","year":"2013","journal-title":"Indian Dermatol. Online J."},{"issue":"8","key":"10.1016\/j.joca.2026.03.116_bib17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-021-01524-y","article-title":"Fostamatinib: A review in chronic immune thrombocytopenia","volume":"81","author":"Paik","year":"2021","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.joca.2026.03.116_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2217\/imt-2020-0215","article-title":"Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia","volume":"12","author":"Newland","year":"2020","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.joca.2026.03.116_bib19","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.joca.2019.05.006","article-title":"Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment","volume":"27","author":"Deshmukh","year":"2019","journal-title":"Osteoarthr. Cartil."},{"issue":"46","key":"10.1016\/j.joca.2026.03.116_bib20","doi-asserted-by":"crossref","first-page":"31972","DOI":"10.1074\/jbc.M109.056838","article-title":"Oxidative stress inhibits insulin-like growth factor-I induction of chondrocyte proteoglycan synthesis through differential regulation of phosphatidylinositol 3-Kinase-Akt and MEK-ERK MAPK signaling pathways","volume":"284","author":"Yin","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.joca.2026.03.116_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.joca.2017.08.015","article-title":"A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee","volume":"26","author":"Deshmukh","year":"2018","journal-title":"Osteoarthr. Cartil."},{"issue":"22","key":"10.1016\/j.joca.2026.03.116_bib22","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.joca.2026.03.116_bib23","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/art.22869","article-title":"Central role of the MEK\/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms","volume":"56","author":"Thiel","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.joca.2026.03.116_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00011-011-0431-5","article-title":"Suppressive effect of an orally active MEK1\/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide","volume":"61","author":"Yamaguchi","year":"2012","journal-title":"Inflamm. Res"},{"key":"10.1016\/j.joca.2026.03.116_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.938133","article-title":"Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.joca.2026.03.116_bib26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.bbrc.2018.02.147","article-title":"A selective c-Fos\/AP-1 inhibitor prevents cartilage destruction and subsequent osteophyte formation","volume":"497","author":"Motomura","year":"2018","journal-title":"Biochem Biophys. Res Commun."},{"issue":"3","key":"10.1016\/j.joca.2026.03.116_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s12276-025-01418-z","article-title":"Blockade of the vaspin-AP-1 axis inhibits arthritis development","volume":"57","author":"Jeon","year":"2025","journal-title":"Exp. Mol. Med"},{"issue":"7","key":"10.1016\/j.joca.2026.03.116_bib28","first-page":"741","article-title":"Trametinib: a targeted therapy in metastatic melanoma","volume":"9","author":"Hoffner","year":"2018","journal-title":"J. Adv. Pr. Oncol."},{"issue":"3","key":"10.1016\/j.joca.2026.03.116_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CMR.0000000000000654","article-title":"Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)","volume":"30","author":"Atkinson","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.joca.2026.03.116_bib30","unstructured":"U.S. Food and Drug Administration. FDA-approved drugs: trametinib. [Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204114s016lbl.pdf\u3009."},{"issue":"4","key":"10.1016\/j.joca.2026.03.116_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular Effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc Toxicol."},{"issue":"3","key":"10.1016\/j.joca.2026.03.116_bib32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00109-012-0953-5","article-title":"Combination of MEK-ERK inhibitor and hyaluronic acid has a synergistic effect on anti-hypertrophic and pro-chondrogenic activities in osteoarthritis treatment","volume":"91","author":"Prasadam","year":"2013","journal-title":"J. Mol. Med"},{"issue":"6","key":"10.1016\/j.joca.2026.03.116_bib33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/art.11014","article-title":"vivo selective inhibition of mitogen-activated protein kinase kinase 1\/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes","volume":"48","author":"Pelletier","year":"2003","journal-title":"Arthritis Rheum."}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458426008058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458426008058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:41:47Z","timestamp":1790595707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458426008058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1063458426008058"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2026.03.116","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening of an FDA-approved drug library reveals MEK1\/2 inhibitors block production of osteoarthritis mediators in activated human chondrocytes and synovial fibroblasts","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2026.03.116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}